France· FR:64349947
OXOGLURATE D’ORNITHINE MYLAN 5 g, poudre pour solution buvable et gastro-entérale en sachet-dose
A medicinal product containing oxoglurate d'ornithine, registered in France by MYLAN SAS.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- OXOGLURATE D'ORNITHINE
- Manufacturer
- MYLAN SAS
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip13340093750753010 sachet(s)-dose(s) papier aluminium polyéthylène de 5,19 g
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/06060670-a50c-41cc-b371-348348d8f8b2 GET /v1/drugs/06060670-a50c-41cc-b371-348348d8f8b2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64349947",
"date_amm": "2006-04-27",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "OXOGLURATE D'ORNITHINE",
"statut_amm": "Autorisation archivée",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "poudre pour solution buvable et gastro-entérale",
"voies_administration": "gastro-entérale;orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about oxoglurate d'ornithine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.